Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Nicholas Valeriani Appointed To Edwards Lifesciences’ Board Of Directors

November 17, 2014
Life sciences
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee.  Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs.  Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee. 
 
“We are pleased to add Nick’s talents and deep experience to a strong board that is guiding Edwards’ focused innovation strategy, as we develop and deliver important therapies to patients in need,” said Michael A. Mussallem, Edwards’ chairman and CEO. “I’m confident that his long career dedicated to improving patients’ lives provides him with a very informed and contemporary view on both the development of groundbreaking devices and also how best to provide them to patients and physicians in an increasingly complex global healthcare system.”
 
Currently, Valeriani serves on the boards of directors of Robert Wood Johnson University Hospital, the Reagan-Udall Foundation, Reflexion Health, Inc., and the Center for Medical Interoperability.
 
Valeriani has a master’s degree in business administration from Rutgers University, Graduate School of Management, and a bachelor’s degree in industrial engineering from Rutgers University, College of Engineering.
 
Source: Edwards Lifesciences

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach